Novavax (NVAX) is back in focus after Sanofi’s Phase 3 influenza COVID-19 combination vaccine trial in the EU hit a dosing milestone, which triggered a US$125 million payment under their collaboration agreement.
Recent trading shows that momentum in Novavax has been choppy rather than one way, with the share price slipping 3.7% over the past day and 3.6% over the past month, yet delivering a 36.0% 90 day share price return and a 41.4% year to date gain. Against that backdrop, the 20.0% one year total shareholder return and 42.8% three year total shareholder return sit beside a 93.7% total shareholder return decline over five years, while the Sanofi milestone and the October reduction in Shah Capital’s activist stance give investors fresh information on both funding prospects and perceived risk.
Capitalize on the renewed attention around Novavax by scanning a curated group of vaccine and biotech plays with resilient balance sheets and funding visibility using the list of solid balance sheet and fundamentals (24 results).Novavax now has a clearer funding line from Sanofi and a sharper share price recovery on the board. The tougher question is whether that story is already reflected in today’s valuation or still trades at a discount.
Most Popular Narrative: 60% Undervalued
On the most followed valuation view, Novavax’s fair value of $25.00 sits well above the last close at $10.08. This puts the focus firmly on whether its partnership model and cost targets can bridge that gap over time.
Planned reduction of combined non GAAP R&D and SG&A to a range of US$150 million to US$200 million by 2028, alongside paying down pandemic era APA liabilities by early 2029, means that incremental royalties and milestones from existing and new Matrix M programs drop into a much leaner cost structure than in prior years. This creates room for a re rating of earnings quality rather than just top line growth.
See why 6 investors see Novavax as 60% undervalued.
Result: Fair Value of $25.00 (UNDERVALUED)
Still, the thesis can break if Matrix M royalties arrive slower than expected and governance frictions around Shah Capital’s criticisms limit Novavax’s execution.
Find out about the key risks to this Novavax narrative.
Next Steps
Mixed messages on Novavax can pull you in opposite directions, so move quickly, review the same numbers, and weigh 2 key rewards and 2 important warning signs
Looking for more investment ideas beyond Novavax?
Do not stop with a single stock. Broaden your watchlist with a few focused sets of companies that match different risk, income, and value goals.
- Target resilient balance sheets and cleaner funding profiles by scanning the list of solid balance sheet and fundamentals (24 results).
- Hunt for quality on sale by reviewing the 33 high quality undervalued stocks before the crowd pays attention.
- Build a cash flow engine by checking the 5 dividend fortresses that can support higher income goals.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com